The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Open accessAbstract
BACKGROUND: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer. METHODS: Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease progression, the development of unacceptable toxic effects, or a complete response was documented. The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was considered clinically important. RESULTS: Groups were well balanced with respect to age, histologic findings, performance status, previous use or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan-paclitaxel was not superior to cisplatin-paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%). CONCLUSIONS: The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8909 · Cited by 693
Self-citationMoore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Long, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.021 · Cited by 556
Self-citationBonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.8.1079 · Cited by 402
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Self-citationMonk, B. J., Mas Lopez, L., Zarba, J. J., Oaknin, A., Tarpin, C., Termrungruanglert, W., Alber, J. A., Ding, J., Stutts, M. W., & Pandite, L. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9571 · Cited by 264
Self-citationMonk, B. J., Tewari, K. S., & Koh, W.-J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8324 · Cited by 261
Self-citationTang, X., Zhang, Q., Nishitani, J., Brown, J. J., Shi, S., & Le, A. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2704 · Cited by 165
Moore, D. H., Tian, C., Monk, B. J., Long, H. J., Omura, G. A., & Bloss, J. D. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.006 · Cited by 158
Self-citationBodily, J. M., Mehta, K. P. M., & Laimins, L. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2626 · Cited by 147
Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer
Tewari, K. S., & Monk, B. J. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0007-z · Cited by 103
Self-citationStopping when the experimental regimen does not appear to help
Wieand, S., Schroeder, G. S., & O'Fallon, J. R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131321 · Cited by 91
Tewari, K. S., & Monk, B. J. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.12.008 · Cited by 55
Self-citationSynergistic interaction between topotecan and microtubule-interfering agents
Bahadori, H. R., Green, M. A., & Catapano, C. V. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100327 · Cited by 49
Clere, N., Bermont, L., Fauconnet, S., Lascombe, I., Saunier, M., Vettoretti, L., Plissonnier, M., & Mougin, C. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.06.029 · Cited by 39
Tewari, K. S., & Monk, B. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07419-3.00003-5 · Cited by 39
Self-citationTewari, K. S., Taylor, J. A., Liao, S. Y., DiSaia, P. J., Burger, R. A., Monk, B. J., Hughes, C. C. W., & Villarreal, L. P. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5729 · Cited by 36
Self-citationNo, J. H., Jo, H., Kim, S., Park, I., Kang, D., Han, S. S., Kim, J., Park, N.-H., Kang, S., & Song, Y. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04891.x · Cited by 27
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Metadata
- Authors
- Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., & Monk, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-20
- Volume
- 370
- Issue
- 8
- Pages
- 734-743
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2100756525
- Cited by
- 1,504
- References
- 26
- FWCI
- 138.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.